Tender No. 1
About This Opportunity
TranslatedThis tender, identified as Tender No. 1 (sub-contract), concerns the procurement of specific pharmaceutical products. The primary focus is on Enfortumab vedotin, an antineoplastic agent classified under ATC code L01FX13. Two distinct strengths are specified: 20 mg and 30 mg, both with an "Enhedsværdi" (unit value) of 9.375 mg. The estimated quantities required are 5818 units for the 20 mg strength and 15587 units for the 30 mg strength. Each tender number is considered an independent sub-contract, and suppliers have the flexibility to bid on one, multiple, or all available tender numbers. Awarding of contracts will be conducted separately for each tender number, meaning a single supplier could be awarded one or more sub-contracts. The description emphasizes that the quantities provided are estimates based on anticipated consumption within public hospitals, and actual usage may vary significantly due to patient-specific treatment needs. Furthermore, the consumption of these medicines is influenced by recommendations and treatment guidelines issued by the Danish Medicines Council (Medicinrådet). These guidelines assess the suitability of the listed pharmaceuticals for various patient populations, potentially establishing preferred first-choice treatments or prioritized usage orders. Suppliers are advised to consult the tender conditions and framework agreement for a comprehensive understanding of the tender, including details on bidding procedures for individual tender numbers. The maximum value of this sub-contract is calculated as 100% of the estimated total value of all sub-contracts, reflecting the comprehensive nature of the procurement and the influence of the Danish Medicines Council's recommendations on drug utilization.
This is a supplies contract in the health and medical services and general supplies sectors, with a focus on Pharmaceuticals and Medical Equipment. Located in Denmark, Europe, this opportunity is open to firms and consortiums, with an estimated budget of DKK 165.0 million.
Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.
Description
Original language: daUdbudsnummeret (delkontrakten) omfatter følgende lægemidler: ATC Kode: L01FX13 · Generisk navn: Enfortumab vedotin · Dispenseringsform: Infusionsvæske · Styrke: 20 mg · Enhedsværdi: 9,375 mg · Mængde i enheder: 5818 ··· ATC Kode: L01FX13 · Generisk navn: Enfortumab vedotin · Dispenseringsform: Infusionsvæske · Styrke: 30 mg · Enhedsværdi: 9,375 mg · Mængde i enheder: 15587. Hvert udbudsnummer anses for en selvstændig delkontrakt og udbydes uafhængigt af de øvrige udbudsnumre. En leverandør kan således vælge at give tilbud på ét, flere eller alle udbudsnumre, og tildeling sker separat for hvert enkelt udbudsnummer. En leverandør kan således tildeles en, flere eller alle delkontrakter. Der henvises til udbudsbetingelserne, herunder om afgivelse af tilbud under de enkelte udbudsnumre. Under betegnelsen "mængde i enheder" ovenfor er angivet et skønnet forbrug af lægemidlerne under udbudsnummeret, men det reelle forbrug kan afvige væsentligt derfra. Dette må leverandørerne påregne. Baggrunden herfor er, at der er tale om lægemidler til patientbehandling på de offentlige sygehuse, hvor patientens behov skal imødekommes. De udbudte lægemidler er endvidere omfattet af en eller flere anbefalinger og/eller behandlingsvejledninger fra Medicinrådet, og forbruget af de forskellige lægemidler kan i væsentligt omfang blive påvirket deraf. For nærmere beskrivelse henvises der til udbudsbetingelserne og rammeaftalen. Den nedenfor under pkt. 5.1.5 maksimale værdi af delkontrakten er beregnet som en andel på 100 % af den anslåede samlede værdi af alle delkontrakter anført i pkt. 2.1.3. Det beror på, at alle de udbudte lægemidler er omfattet af en eller flere anbefalinger og/eller behandlingsvejledninger fra Medicinrådet, som vurderer, hvilke af de udbudte lægemidler der anbefales til behandling til forskellige patientpopulationer, eventuelt således at visse lægemidler anses som ligestillede mulige førstevalg, anbefales til anvendelse i prioriteret rækkefølge eller lignende. Medicinrådets vurdering kan derfor have væsentlig betydning for, hvilke af de udbudte lægemidler der anvendes inden for forskellige terapiområder og patientpopulationer, og forbruget af de enkelte lægemidler kan tillige bero på gældende aftalepriser. Det betyder, at det ved udbuddet ikke er muligt at anslå, hvilke lægemidler der primært vil blive anvendt under rammeaftalens løbetid, og det er muligt, at anvendelse af lægemidlerne kan ændres betydeligt under rammeaftalernes løbetid, herunder navnlig ved godkendelse af nye indikationer for de enkelte lægemidler, ændret behandling af en eller flere patientpopulationer og lignende. Fastsættelse af den maksimale værdi af de enkelte delkontrakter som en andel af den samlede anslåede mængde af alle delkontrakter har til formål at sikre, at hver af de indgåede rammeaftaler kan anvendes til det fornødne indkøb. Den maksimale værdi er således fastsat på grundlag af en faglig vurdering af den potentielle anvendelse af lægemidlerne henset til de særlige omstændigheder vedrørende anvendelse af lægemidler på de offentlige sygehuse og den væsentlige betydning, som Medicinrådets anbefaling og/eller behandlingsvejledning kan have for det faktiske forbrug af de enkelte lægemidler, herunder væsentlig ændring i forbruget af de forskellige lægemidler.
Data provenance
This notice is sourced from TED - Tenders Electronic Daily (EU) and was originally published on December 16, 2025. Last refreshed 1 day ago. Original language: da. BidsFactory mirrors official procurement notices and links back to the source for full legal text.
About Amgros I/S
Amgros I/S has issued 139 procurement notices on BidsFactory, including 27 currently open and 51 awarded contracts. Activity concentrates in Health & Medical, General Supplies & Services, and Media & Communications. All notices are published for Denmark. Notices are distributed via TED - Tenders Electronic Daily (EU) and Denmark Udbud. Most recent publication: May 19, 2026.
Frequently asked questions about this tender
Where will the contract be performed?
The contract is for delivery in Denmark. Foreign bidders should review local registration, taxation, and any in-country presence requirements before submitting.
How can I submit a bid?
Visit TED - Tenders Electronic Daily (EU) to access the full notice, required documents, and submission instructions provided by the contracting authority.
Is this tender still open?
No — the contract has already been awarded to Astellas Pharma A/S. The award notice is archived on BidsFactory for transparency and market intelligence.
Who is the contracting authority?
This notice was issued by Amgros I/S in Denmark. The authority is responsible for evaluating bids, awarding the contract, and managing performance.
What type of contract is this?
This is a Supplies contract in the Health & Medical sector. The classification helps bidders match the opportunity to their qualifications and registered scope of supply.
How much was the contract awarded for?
Astellas Pharma A/S was awarded the contract for DKK 165,000,000. The figure reflects the value disclosed by the contracting authority in the award notice.
Find tenders like this automatically
Set up alerts and filters that match your business — never miss a relevant opportunity again.